Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C1S | P09871 | 8/20 | 0.81 |
| ▸ | PLAU | P00749 | 9/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | PLG | P00747 | 2/20 | 0.45 |
| ▸ | PLAT | P00750 | 2/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6920317 | 0.90 | C1S (1.00) | C1SPLAUPLGPLATPRSS1 | |
| SCHEMBL6925269 | 0.79 | C1S (0.81) | C1SPLAUPLGPLATPRSS1 | |
| SCHEMBL6921168 | 0.76 | C1S (0.76) | C1SPLAUPLGPLATPRSS1 | |
| SCHEMBL15698845 | 0.75 | HSPA5 (0.65) | C1SUSP2TP53MAPTLMNA | |
| SCHEMBL6926742 | 0.74 | PLAU (1.00) | C1SPLAUPLGPLATPRSS1 | |
| SCHEMBL6925245 | 0.73 | PLAU (0.81) | C1SPLAUPLGPLATPRSS1 | |
| SCHEMBL6925434 | 0.71 | C1S (0.70) | C1SPLAUPLGPLATPRSS1 | |
| Trifluoroacetic Acid SCHEMBL7130879 | 0.71 | PLAU (0.83) | C1SPLAUPLGPLATPRSS1 | |
| SCHEMBL2810572 | 0.69 | PLAU (1.00) | C1SPLAUPLGPLATPRSS1 | |
| SCHEMBL7827575 | 0.69 | PLAU (0.69) | C1SPLAUPLGPLATPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515002-B2 | 4-(4-(1-phenyl-5-propylpyrazol4-yl)(1,3-thiazol-2-yl))-5 -methylthiothiophene-2-carboxamidine, for example; complement inhibitors; treating tissue damage, inflammation, or autoimmune diseases | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| US-6492403-B1 | TREATING SYMPTOMS OF ACUTE OR CHRONIC DISORDER MEDIATED BY CLASSICAL PATHWAY OF COMPLEMENT CASCADE; PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1152759-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000047194-A9 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | DIMENSIONAL PHARM INC (US) | 2001-05-31 | — | — | WO | disclosed |
| WO-2000047194-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |